Clearmind Medicine says Japan published dyskinesia patent application
The company says its 3-MMC claims cover dyskinesia treatment alone and with PEA, but gave no publication number or grant timetable.
Theo Marchetti
Japan has published a patent application for a proposed dyskinesia treatment, according to an Oct. 8 announcement.
Clearmind Medicine Inc. NASDAQCMND says the application seeks claims for 3-MMC alone and with palmitoylethanolamide, or PEA. The Vancouver developer counted 19 patent families and 32 granted patents in its portfolio in the same Oct. 8 release.
Clearmind shares NASDAQCMND rose 1.75 per cent to US$6.72 on Nasdaq by 11:30 a.m. EDT Thursday. Clearmind describes itself as a clinical-stage developer pursuing psychedelic-derived compounds, with alcohol use disorder among its programs.
The application covers methods of preventing, treating or reducing symptoms of dyskinesia, which Clearmind describes as a disorder involving involuntary movements. It also seeks claims for pharmaceutical compositions containing 3-MMC and combinations with a class of compounds called N-acylethanolamines, including PEA.
Publication Does Not Grant a Patent Right
Publication makes the request visible, but it does not establish a patent right. The Japan Patent Office's procedure guide says an application is examined only when the applicant or another party requests examination. Review can lead to a patent grant or a refusal, and the claims that survive need not match those first published.
Clearmind's Oct. 8 release gives no Japanese publication number, filing date or examination-request date. It does not reproduce the claims or name the applicant listed in the Japanese filing. The application itself was not read for this report, so its exact claim language remains unchecked; the company gave no timetable for a Japanese decision. The release does not say whether Japan's patent office has examined, narrowed or allowed any of the proposed claims.
"Our strategy is to build robust intellectual property protection around our novel therapeutic platforms and their broad potential across neurological disorders," Clearmind chief executive Adi Zuloff-Shani said in the release.
Clearmind's cautionary language says a pending application may never issue as a patent, and that any patent granted might not be advantageous to the company. Those cautions apply to the Japanese claim as well as the company's wider effort to protect its compounds.
The Filing Is Part of a Pending Program
The company's science and intellectual property page lists 3-MMC for dyskinesia among applications it describes as pending worldwide. The same page lists other proposed uses for the compound, while the Oct. 8 announcement deals specifically with dyskinesia and a Japanese publication. It does not report a treatment approval.
The release contains no dyskinesia trial phase, patient count, clinical endpoint or efficacy result. Its proposed uses therefore remain patent claims rather than clinical findings, and the company's count of 32 granted patents does not include a newly granted Japanese dyskinesia patent.
Clearmind's Oct. 8 announcement gives no date for an examination request or decision. A Japanese grant or refusal after review will determine whether the published claims become a patent.
